Evidence map›Paper›PMID 40869384›Full record

ArticleInternational journal of molecular sciences2025

Immune Modulation Through KIR-HLA Interactions Influences Cetuximab Efficacy in Colorectal Cancer.

María Gómez-Aguilera, Bárbara Manzanares-Martín, Arancha Cebrián-Aranda, Antonio Rodríguez-Ariza, Rafael González-Fernández, Laura Del Puerto-Nevado, Jesús García-Foncillas, Enrique Aranda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

María Gómez-AguileraMedical Oncology Department, Reina Sofia University Hospital, University of Cordoba, 14071 Cordoba, Spain.
Bárbara Manzanares-MartínDepartment of Immunology and Allergy, Reina Sofía University Hospital, 14004 Cordoba, Spain.
Arancha Cebrián-ArandaTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Autonomous University of Madrid, 28040 Madrid, Spain.
Antonio Rodríguez-ArizaMedical Oncology Department, Reina Sofia University Hospital, University of Cordoba, 14071 Cordoba, Spain.ORCID 0000-0001-5304-5745
Rafael González-FernándezDepartment of Immunology and Allergy, Reina Sofía University Hospital, 14004 Cordoba, Spain.
Laura Del Puerto-NevadoTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Autonomous University of Madrid, 28040 Madrid, Spain.
Jesús García-FoncillasTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Autonomous University of Madrid, 28040 Madrid, Spain.
Enrique ArandaMedical Oncology Department, Reina Sofia University Hospital, University of Cordoba, 14071 Cordoba, Spain.

Funding

Instituto de Salud Carlos III CIBERONC-CB16/12/00349
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a major cause of cancer-related mortality. Cetuximab improves survival by combining EGFR inhibition with immune activation. This study evaluated the influence of killer cell immunoglobulin-like receptor (KIR)-mediated immune responses on cetuximab efficacy in 124 metastatic CRC patients: 55 with wild-type (WT) KRAS and 69 with KRAS mutations. Peripheral blood was genotyped for 19 KIR genes and relevant HLA alleles, focusing on key KIR-HLA interactions (2DL1-C2, 3DL1-Bw4, 3DS1-Bw4). KRAS-WT patients showed better outcomes, receiving more treatment cycles (median: 17 vs. 4) and showing slower disease progression (60% vs. 92.8% at 12 months). WT patients had higher frequencies of inhibitory KIRs and the Bw4 allele, with KIR3DS1-Bw4 heterozygosity linked to longer survival (

Indexed as

Antineoplastic Agents, ImmunologicalCetuximabColorectal NeoplasmsHLA AntigensReceptors, KIRAdultAgedAged, 80 and overAllelesFemaleGenotypeHumansMaleMiddle AgedMutationProto-Oncogene Proteins p21(ras)Antineoplastic Agents, ImmunologicalCetuximabHLA AntigensKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptors, KIRanti-EGFRcetuximabHLA ligandsKIRmetastatic colorectal cancernatural killer cells

Identifiers

PMID40869384
PMCPMC12386678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.